Weiying Yang specializes in intellectual property matters that relate to the chemical arts, including pharmaceutical matters.  Her fields of expertise include organic and inorganic chemistry and polymer sciences. 
 
Prior to joining Synnestvedt & Lechner, Ms. Yang had seven years of industrial experience as a medicinal chemist working for Schering-Plough Research Institute. She is a listed inventor for several Hepatitis C drug applications filed by Schering-Plough Corporation.

Ms. Yang earned her undergraduate degree in applied chemistry from Peking University, People's Republic of China (B.S., 1996) and her graduate degree in organic chemistry from the University of Pennsylvania (M.S., 2000).  She earned her first law degree with specialty in Intellectual Property from Peking University, People's Republic of China (LL.B., 1997) and her J.D. from Rutgers, Newark, School of Law (J.D., 2006).

Ms. Yang is registered to practice before the U.S. Patent and Trademark Office and is admitted to practice in the State of New Jersey. She joined Synnestvedt & Lechner LLP in 2007 as an associate.

Year Joined Organization:

2007

Practice Grpup(s):

Chemical and ChemPharma

Bar Admissions:

New Jersey
U.S. Patent and Trademark Office

Education:

Rutgers University School of Law, Newark, NJ, 2006
J.D.

University of Pennsylvania, 2000
M.S.
Major: Organic Chemistry

Peking University, People's Republic of China, 1997
LL.B.

Peking University, People's Republic of China, 1996
B.S.
Major: Applied Chemistry

Past Employment Positions:

Schering-Plough Research Institute, 2000 - 2007
Medicinal Chemist

Published Works:

“Novel Potent Hepatitis C Virus NS3 Serine Protease Inhibitors Derived from Proline- Based  Macrocycles.” J. Med. Chem. 2006

“Discovery of (1R, 5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection.” J. Med. Chem. 2006

“Discovery of SCH 503034, a selective, potent HCV NS3 protease inhibitor with oral bioavailability: Potential therapeutic agent for treating hepatitis C viral infection.”   Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, 2005

Honors and Awards:

President’s Award for Excellence in Research, Schering-Plough Research Institute, 2003

Languages:

Mandarin Chinese (native language)